Longevity, built around you.Licensed US clinicians·Third-party tested

Press & media

What we can speak to, and what we won't.

Peptós.LIFE is a clinician-supervised US telehealth company that also publishes a public FDA peptide tracker and knowledge base. We can speak on the record about peptide regulatory status, the 503A Bulks List, the PCAC process and compounding policy. We do not comment on dosing, protocols, or any individual's medical decisions.

Media contact: hello@peptos.life · put PRESS in the subject line · we aim to reply within one business day, and we will tell you if we can't answer rather than answer vaguely.

The boundary

Published so you can hold us to it.

Most of what makes a source usable is knowing in advance where it stops. Ours is written down.

We comment on

  • Where a specific peptide actually stands with the FDA, on the record, with the docket.
  • The 503A Bulks List and how the PCAC process works — what an advisory vote is, and what it is not.
  • Compounding policy: 503A versus 503B, the shortage-exception pathway, and what the April 2026 Category 2 change did and did not do.
  • How to evaluate a provider, and what a reader should be able to verify for themselves.
  • Our own method: how we grade evidence, how a status changes, and where we have been wrong.

We do not comment on

  • Dosing. Any amount, any schedule, any route — not on background, not off the record.
  • Protocols or stacks as instruction for a reader to follow.
  • Any individual's medical decision, or anything that would read as advice to a named person.
  • Whether a peptide "works." We will tell you what the human evidence is and what grade we give it; we will not translate that into a verdict on efficacy.
  • Another company's practices, by name or by a description specific enough to identify one.
  • Anything about a commercial relationship beyond what is signed and public.

Citable data

The FDA Tracker, and how to cite it.

The FDA Peptide Tracker carries one row per tracked molecule and keeps two signals that are never merged: the regulatory status (what the rule currently says) and a plain-English access verdict (whether anyone can actually get it). Neither is derived from the other, because they answer different questions and routinely disagree — a molecule can be PCAC-recommended and still not be lawful to compound.

Status changes trace to primary sources: the Federal Register, the FDA dockets, and the committee record. Board-level freshness is stamped on the page — currently July 26, 2026 — and every molecule carries its own review date rather than inheriting a sitewide one. We update within 24 hours of an FDA action on a tracked molecule.

The machine-readable dataset is at /fda-tracker.json, declared with Dataset schema on the tracker itself. It is licensed CC BY 4.0: journalists and researchers may use, quote, chart and republish it freely with attribution to Peptós.LIFE and a link. No permission request, no embargo, no key. There is a per-molecule embeddable card at /embed under the same licence.

A second PCAC review is expected before the end of February 2027 covering LL-37, GHK-Cu, Dihexa, Melanotan II and PEG-MGF. Those rows are on the tracker now with their current status, so a story filed ahead of it can be built on dated fact rather than on our characterisation of it.

Who you can quote

Named humans, or nothing.

We have not published a named spokesperson yet, and we are not going to pretend otherwise. An unnamed spokesperson is worse than none, and a name without a verifiable licence record is worse still. Our review standards and the process behind every status call are public at /medical-review. For an interview we will put a named, credentialed clinician on the record with a state licence number you can look up before you publish — email hello@peptos.life and we will name them in the reply, not on a call.

Methodology

How the calls get made.

  • Evidence grading. Every molecule carries an A–E human-evidence grade with the reasoning stated, not a score. The full method is public at /peptides/how-we-grade. A widely discussed molecule with thin human data still gets a thin grade.
  • How an access verdict moves. Only on confirmed fulfilment — a licensed pharmacy able to fill a prescription written by a clinician licensed in the patient's state. Never on a committee vote, never on a comment period closing, never on a rumour. An advisory recommendation moves the regulatory signal and leaves the access signal exactly where it was.
  • Corrections. If we get something wrong we change it, date the change, and leave the fact of the correction visible on the page rather than editing silently. Email hello@peptos.life with PRESS in the subject and we will treat it as a correction request.
  • Our public standard for partner claims. The rules a creator must follow when talking about peptides on our behalf are published, unpaid and ungated at /partners/compliance, including a live list of the molecules nobody may promote. It is there so you can check our partners against it.

Assets

Logos, cleared for editorial use.

Free to reproduce in editorial coverage. Don't alter the marks, recolour them, or use them in a way that implies we endorse the piece.

Tracker screenshots at publication resolution, and headshots once a spokesperson is named, on request to hello@peptos.life — we would rather send you a current screenshot than host one that goes stale. Screenshots of the tracker may be reproduced under CC BY 4.0 with attribution.

Our regulatory coverage

What we have published, dated.

This is our own writing on the record — not a list of who has covered us.

All posts: the newsroom · RSS

Last reviewed · Peptós.LIFE · Not medical advice.